{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T07:19:45Z","timestamp":1775719185237,"version":"3.50.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100011015","name":"International Society of Travel Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Data on seroconversion rates following yellow fever (YF) vaccine and effect of revaccination in people living with HIV (PLWH) are scarce. We aimed at determining key factors for seroconversion after YF vaccine in PLWH and the role of preexisting neutralizing antibodies (NAbs) at vaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective cross-sectional study at several timepoints in two Belgian AIDS Reference Center. For each individual, plasma samples from three timepoints were selected: Timepoint 0 (TP0) in the year before administration of the YF vaccine, Timepoint 1 (TP1) in the year following the YF vaccine, Timepoint 2 (TP2) &amp;gt;1\u00a0year after the YF vaccine. Plasma samples were analysed for YF NAbs by plaque reduction neutralization test. The primary endpoint was the number of patients with protective levels of NAbs\u2009\u2265\u20091\/10. A boosted immune response was defined as a 4-fold increase in serologic titres following revaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 160 PLWH included, protective levels of NAbs were present in 36%, 87% and 72% of subjects at baseline, at a median of 12\u00a0months and a median of 96\u00a0months after YF vaccination, respectively. Among vaccine recipients negative for YF NAbs at baseline (n\u2009=\u2009102), 83% seroconverted. PLWH with undetectable HIV viral load (VL) at baseline were more likely to seroconvert (P\u2009&amp;lt;\u20090\u00b701). A booster response was observed in only 17% of subjects with baseline seropositivity (n\u2009=\u200910 out of 58). In multivariate analysis, undetectable HIV VL at vaccination and baseline YF seropositivity were associated with persistent levels of protective NAbs at a median of 8\u00a0years after YF vaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Undetectable HIV VL at baseline is associated with high rates of seroconversion. YF seropositivity before revaccination is associated with low rates of booster effect but a higher chance of long term persistent NAbs response, suggesting a benefit of revaccination in PLWH.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jtm\/taac024","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T20:09:49Z","timestamp":1646942989000},"source":"Crossref","is-referenced-by-count":12,"title":["Seroconversion and antibody persistence after yellow fever vaccination in people living with HIV: impact of baseline HIV viral load and yellow fever seropositivity"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8995-6230","authenticated-orcid":false,"given":"Charlotte","family":"Martin","sequence":"first","affiliation":[{"name":"Infectious Diseases Department , Saint-Pierre University Hospital, , 1000 Brussels , Belgium"},{"name":"Universit\u00e9 Libre de Bruxelles (ULB) , Saint-Pierre University Hospital, , 1000 Brussels , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Florence","sequence":"additional","affiliation":[{"name":"Institute of Tropical Medicine , 2000 Antwerp , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Domingo","sequence":"additional","affiliation":[{"name":"Robert Koch Institute, Centre for Biological Threats and Special Pathogens - Highly Pathogenic Viruses- ZBS-1 , 13353 Berlin , Germany"},{"name":"Robert Koch Institute, Centre for International Health Protection (ZIG) -ZIG-4 Public Health Laboratory Support , 13353 Berlin , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Delforge","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department , Saint-Pierre University Hospital, , 1000 Brussels , Belgium"},{"name":"Universit\u00e9 Libre de Bruxelles (ULB) , Saint-Pierre University Hospital, , 1000 Brussels , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"De Wit","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department , Saint-Pierre University Hospital, , 1000 Brussels , Belgium"},{"name":"Universit\u00e9 Libre de Bruxelles (ULB) , Saint-Pierre University Hospital, , 1000 Brussels , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Dauby","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department , Saint-Pierre University Hospital, , 1000 Brussels , Belgium"},{"name":"Universit\u00e9 Libre de Bruxelles (ULB) , Saint-Pierre University Hospital, , 1000 Brussels , Belgium"},{"name":"Institute for Medical Immunology , , 1070 Brussels , Belgium"},{"name":"Universit\u00e9 Libre de Bruxelles (ULB) , , 1070 Brussels , Belgium"},{"name":"School of Public Health , , 1070 Brussels , Belgium"},{"name":"Universit\u00e9 Libre de Bruxelles (ULB) , , 1070 Brussels , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"key":"2022122710505680000_ref1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.tmaid.2013.06.009","article-title":"Trends and characteristics among HIV-infected and diabetic travelers seeking pre-travel advice","volume":"12","author":"Elfrink","year":"2014","journal-title":"Travel Med Infect Dis"},{"key":"2022122710505680000_ref2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.tmaid.2019.03.010","article-title":"Travel-related health events and their risk factors in HIV-infected sub-Saharan migrants living in France and visiting their native country: the ANRS VIHVO cohort study","volume":"29","author":"Pistone","year":"2019","journal-title":"Travel Med Infect Dis"},{"key":"2022122710505680000_ref3","doi-asserted-by":"crossref","first-page":"102192","DOI":"10.1016\/j.tmaid.2021.102192","article-title":"Yellow fever reemergence in Venezuela \u2013 implications for international travelers and Latin American countries during the COVID-19 pandemic","volume":"44","author":"Rodr\u00edguez-Morales","year":"2021","journal-title":"Travel Med Infect Dis"},{"key":"2022122710505680000_ref4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2021.1891752","article-title":"Yellow fever virus vaccination: an emblematic model to elucidate robust human immune responses","volume":"17","author":"Bovay","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"2022122710505680000_ref5","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1086\/511869","article-title":"Yellow fever: epidemiology and prevention","volume":"44","author":"Barnett","year":"2007","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"2022122710505680000_ref6","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.4269\/ajtmh.16-0401","article-title":"A meta-analysis of serological response associated with yellow fever vaccination","volume":"95","author":"Jean","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"2022122710505680000_ref7","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3201\/eid2508.181432","article-title":"17DD yellow fever revaccination and heightened long-term immunity in populations of disease-endemic areas, Brazil","volume":"25","author":"Campi-Azevedo","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"2022122710505680000_ref8","doi-asserted-by":"crossref","first-page":"6327","DOI":"10.1016\/j.vaccine.2011.05.019","article-title":"Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella","volume":"29","author":"Nascimento Silva","year":"2011","journal-title":"Vaccine"},{"key":"2022122710505680000_ref9","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S1473-3099(19)30323-8","article-title":"Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study","volume":"19","author":"Domingo","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2022122710505680000_ref10","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4269\/ajtmh.13-0264","article-title":"Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years","volume":"89","author":"Gotuzzo","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"2022122710505680000_ref11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41541-020-0205-6","article-title":"Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection","volume":"5","author":"Staples","year":"2020","journal-title":"Npj Vaccines"},{"key":"2022122710505680000_ref12","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/tay108","article-title":"Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers","volume":"25","author":"Lindsey","year":"2018","journal-title":"J Travel Med"},{"key":"2022122710505680000_ref13","first-page":"1181","volume-title":"Plotkin\u2019s Vaccines","author":"Staples","edition":"7th"},{"key":"2022122710505680000_ref14","first-page":"1691","volume-title":"Plotkin\u2019s Vaccines","author":"Plotkin","year":"2018","edition":"7th edn"},{"key":"2022122710505680000_ref15","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1084\/jem.20181124","article-title":"Widespread B cell perturbations in HIV-1 infection afflict naive and marginal zone B cells","volume":"216","author":"Liechti","year":"2019","journal-title":"J Exp Med"},{"key":"2022122710505680000_ref16","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1097\/00002030-200309260-00002","article-title":"Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection","volume":"17","author":"Lange","year":"2003","journal-title":"AIDS Lond Engl"},{"key":"2022122710505680000_ref17","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2021.03.004","article-title":"Immunogenicity and duration of protection after yellow fever vaccine in people living with human immunodeficiency virus: a systematic review","author":"Martin","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2022122710505680000_ref18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/(SICI)1096-9071(199810)56:2<159::AID-JMV10>3.0.CO;2-B","article-title":"Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection","volume":"56","author":"Reinhardt","year":"1998","journal-title":"J Med Virol"},{"key":"2022122710505680000_ref19","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.vaccine.2005.12.055","article-title":"Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine","volume":"24","author":"Hepburn","year":"2006","journal-title":"Vaccine"},{"key":"2022122710505680000_ref20","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.3389\/fimmu.2019.01787","article-title":"Remembrance of things past: long-term B cell memory after infection and vaccination","volume":"10","author":"Palm","year":"2019","journal-title":"Front Immunol"},{"key":"2022122710505680000_ref21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11904-019-00461-6","article-title":"Hepatitis B vaccination and waning hepatitis B immunity in persons living with HIV","volume":"16","author":"Farooq","year":"2019","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2022122710505680000_ref22","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/cid\/cit937","article-title":"Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis","volume":"58","author":"Kern\u00e9is","year":"2014","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"2022122710505680000_ref23","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/QAD.0b013e32834411a8","article-title":"Reduced immunogenicity of influenza vaccines in HIV-infected compared with uninfected pregnant women is associated with regulatory T cells","volume":"25","author":"Richardson","year":"2011","journal-title":"AIDS Lond Engl"},{"key":"2022122710505680000_ref24","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/cid\/cix960","article-title":"Long-term immune response to yellow fever vaccination in human immunodeficiency virus (HIV)-infected individuals depends on HIV RNA suppression status: implications for vaccination schedule","volume":"66","author":"Veit","year":"2018","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"2022122710505680000_ref25","doi-asserted-by":"crossref","first-page":"230","DOI":"10.4269\/ajtmh.1963.12.230","article-title":"Immunological studies with group B arthropod-borne viruses. IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine","volume":"12","author":"Rosenzweig","year":"1963","journal-title":"Am J Trop Med Hyg"},{"key":"2022122710505680000_ref26","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1172\/JCI75429","article-title":"Immune activation alters cellular and humoral responses to yellow fever 17D vaccine","volume":"124","author":"Muyanja","year":"2014","journal-title":"J Clin Invest"},{"key":"2022122710505680000_ref27","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/tay130","article-title":"Ten yearly yellow fever booster vaccinations may still be justified","volume":"25","author":"Plotkin","year":"2018","journal-title":"J Travel Med"},{"key":"2022122710505680000_ref28","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1097\/QAD.0b013e32835edc47","article-title":"B-cell subset\u00a0alterations and correlated factors in HIV-1 infection","volume":"27","author":"Pensieroso","year":"2013","journal-title":"AIDS"},{"key":"2022122710505680000_ref29","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/infdis\/jiz679","article-title":"Early antiretroviral therapy may preserve vaccine responses in HIV infected patients by preventing damage to long-lived plasma cells","volume":"222","author":"Nilsson","year":"2019","journal-title":"J Infect Dis"},{"key":"2022122710505680000_ref30","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/tay134","article-title":"Waning immunity after single-dose yellow fever vaccination: who needs a second shot?","volume":"26","author":"Visser","year":"2019","journal-title":"J Travel Med"},{"key":"2022122710505680000_ref31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/QAD.0000000000003114","article-title":"A 5-year neutralizing immune response to yellow fever vaccine in HIV-infected and HIV-uninfected adults","volume":"36","author":"Durier","year":"2022","journal-title":"AIDS Lond Engl"}],"container-title":["Journal of Travel Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jtm\/advance-article-pdf\/doi\/10.1093\/jtm\/taac024\/42959977\/taac024.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/29\/8\/taac024\/48419860\/taac024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/29\/8\/taac024\/48419860\/taac024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T10:51:42Z","timestamp":1672138302000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jtm\/article\/doi\/10.1093\/jtm\/taac024\/6548118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,3,14]]},"published-print":{"date-parts":[[2022,12,27]]}},"URL":"https:\/\/doi.org\/10.1093\/jtm\/taac024","relation":{},"ISSN":["1195-1982","1708-8305"],"issn-type":[{"value":"1195-1982","type":"print"},{"value":"1708-8305","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12]]},"published":{"date-parts":[[2022,3,14]]},"article-number":"taac024"}}